Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics
Moderate Asthma
About this trial
This is an interventional treatment trial for Moderate Asthma focused on measuring sodium pyruvate, anti-inflammatory, bronchodilation, asthma, asthmatics
Eligibility Criteria
Inclusion Criteria: A physician diagnosis of asthma Age years old Symptoms consistent with asthma for at least 6 months Current asthma medications: Short-acting inhaled beta agonists as needed for control of asthma symptoms with or without a low to medium dose of an ICS, as defined in the table below and if on a ICS may also be on a long-acting beta agonist provided it is withheld for 24 hours prior to the testing days. Inhaled Corticosteroid Dose less than or equal to: Beclomethasone-HFA 480 µg/day Budesonide-DPI 1000 µg/day Flunisolide 2000 µg/day Fluticasone 500 µg/day Triamcinolone 2000 µg/day FEV1 at screening 50-80% predicted (Hankinson6) Reversibility with albuterol of 12% and 200 ml FEV1FEV1 at 30 minutes. Exclusion Criteria: -
Sites / Locations
- David Geffen School of Medicine, UCLA